New hope for breast cancer patients with brain spread: drug combo plus radiation trial opens

NCT ID NCT06016387

Recruiting now Disease control Sponsor: Sunnybrook Health Sciences Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for people with HER2+ breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease). It combines targeted drugs (tucatinib, trastuzumab, capecitabine) with radiation to the brain or spine. The goal is to see if this approach helps people live longer and keeps the cancer from growing in the central nervous system. About 30 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm HER2 positive breast carcinoma Langer mesomelic dysplasia Meningeal Neoplasms neoplastic meningitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CANCER LMD

Contacts and locations

Locations

Sunnybrook Health Sciences Centre
RECRUITING

Toronto, Ontario, M4N 3M5, Canada
The Ottawa Hospital
RECRUITING

Ottawa, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.